MarketVIEW Gene Therapy & Ophthalmology  ·  February 2026 edition  ·  with GeneScope Intelligence

Wet AMD
Gene Therapy Commercial Forecast

Wet age-related macular degeneration currently imposes a chronic, lifelong injection burden on millions of patients worldwide. That is about to change: three gene therapy programmes have reached Phase 3, each offering the realistic prospect of durable, injection-free vision preservation from a single administration. This is the independent, patient-based commercial assessment to 2040, built on VacZine Analytics' long-standing, independent authority in vaccine and infectious-disease intelligence since 2007, now extended into gene therapy through our specialist division, GeneScope Intelligence.

3 Phase 3 Programmes Up To 92% Injection Reduction 2028 First Approval Expected 10-Market Forecast to 2040 $3.5bn Opportunity by 2033
Product catalogue
VAMVG003
February 2026 edition

Format
PDF + Excel model
Coverage
10 high-income markets
Programmes assessed
4D-150, RGX-314, ADVM-022
Forecast horizon
2026 to 2040
Approach
Patient-based, bottom-up
Produced with
GeneScope Intelligence
Availability
Syndicated / bespoke
2-3M
Wet AMD patients across
the US and EU5 alone
$3.5bn
Projected 2033 gene
therapy revenue, base case
3
Gene therapy programmes
now in pivotal Phase 3 trials
2027-28
Window for Phase 3 readouts
and first US approval
Disease background

Why wet AMD has become a gene therapy priority

Wet age-related macular degeneration is the leading cause of severe, rapid vision loss in older adults across the developed world. Understanding its biology, and the injection burden it imposes on patients, physicians and payers alike, is central to understanding why a one-time gene therapy is such a compelling proposition.

Peer-reviewed & 2026 pipeline data

Disease overview - Wet (neovascular) age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of severe visual impairment and blindness in adults over 50 across the developed world. Around 85 to 90% of cases are the dry (atrophic) form, but the remaining 10 to 15%, wet or neovascular AMD, is responsible for the majority of severe vision loss. Wet AMD is driven by pathological choroidal neovascularisation: abnormal, VEGF-mediated blood vessels grow beneath and into the retina, leaking fluid and blood. Left untreated, this produces rapid, often severe central vision loss over weeks to months, in sharp contrast to the slow, gradual decline typical of dry AMD. Hallmark symptoms include metamorphopsia (visual distortion of straight lines) and a central scotoma, a blind or blurred patch directly in the patient's line of sight.

Risk rises sharply with age, particularly from the mid-sixties onward, and the strongest modifiable risk factor is smoking. Family history and genetic variants in CFH and ARMS2/HTRA1 also confer materially elevated risk, and prevalence is higher in populations of European ancestry, though the burden is rising across all regions. Global AMD prevalence was estimated at approximately 196 million people in 2020, and is projected to rise to around 288 million by 2040 as the world's population ages. The trend is especially visible in Asia, where age-standardised wet AMD prevalence more than doubled between 2013 and 2022, from roughly 10.7 to 22.5 per 1,000 people, reflecting both population ageing and improving diagnostic capacity.

Within the wet AMD subtype specifically, an estimated 2 to 3 million patients across the United States and EU5 alone rely on chronic intravitreal anti-VEGF therapy, Eylea HD (aflibercept 8mg), Vabysmo (faricimab), Lucentis and a growing biosimilar field, to preserve the vision gains these drugs deliver. The efficacy is genuinely strong, but the treatment model is straining under its own weight: patients require 6 to 12 or more injections per year, indefinitely, and real-world studies consistently show that around half of patients are undertreated relative to clinical recommendations. Injection anxiety, travel burden and caregiver fatigue drive non-compliance, and non-compliance drives preventable vision loss. The global anti-VEGF market generates an estimated $10 billion annually in wet AMD alone, within a total ophthalmic anti-VEGF market that exceeded $17 billion in 2024.

This is precisely why single-administration gene therapy is such a compelling proposition. It does not need to outperform anti-VEGF on efficacy, it only needs to demonstrate non-inferiority on vision outcomes while removing most of the injection burden. Early Phase 1/2 data already show 80 to 92% reductions in injection frequency, and 73 to 80% of patients injection-free at 18 months. If confirmed in the Phase 3 trials now underway, the value proposition for patients, physicians and payers alike would be transformative, and even a modest 15 to 20% share of the treated population would represent a multi-billion-dollar opportunity at one-time, premium pricing.

2026 2-3M wAMD patients (US+EU5)  |  $17bn+ anti-VEGF ophthalmic market (2024)  |  up to 92% injection burden reduction  |  2028 first anticipated approval
Product & competitor landscape

Three Phase 3 programmes - one injection-free ambition

Three gene therapy programmes have reached Phase 3 in wet AMD, each with a distinct vector, route of administration and transgene strategy. How these three sequence into the market, and how physicians and payers respond to the surgical-versus-office-based delivery trade-off, will define the competitive structure of the 2028 to 2033 period.

  • 4D Molecular TherapeuticsMost advanced
    4D-150 Novel AAV, intravitreal
    Novel AAV R100 capsid enabling office-based intravitreal delivery, carrying a dual transgene payload (aflibercept plus a VEGF-C miRNA). Widely regarded as the most advanced and differentiated programme. Pivotal 4FRONT-1 (n=400, US) and 4FRONT-2 (n=400, global) trials are underway, with readouts expected H1 and H2 2027 respectively.
  • Regenxbio / AbbVieFirst pivotal readout
    ABBV-RGX-314 (suravec) AAV8, subretinal
    AAV8 vector delivered subretinally in its pivotal wet AMD programme (a suprachoroidal delivery route is being developed separately for diabetic retinopathy). First of the three to reach a pivotal readout, via the ATMOSPHERE (~630 patients) and ASCENT (~660 patients) trials, expected Q4 2026, but its subretinal delivery requires a surgical procedure, a meaningful commercial and adoption consideration versus office-based alternatives.
  • Adverum BiotechnologiesLongest durability data
    ADVM-022 (ixo-vec) AAV2.7m8, intravitreal
    AAV2.7m8 vector delivered by intravitreal injection. Has generated the longest durability data among the intravitreal candidates. Phase 3 ARTEMIS (n approximately 284) is underway with a planned companion AQUARIUS Phase 3 trial, and the Phase 2 LUNA study continues; topline data expected around Q1 2027.
  • Second-wave & adjacent pipelineVarious
    Earlier-stage intravitreal, subretinal and China-based candidates
    Additional intravitreal and subretinal candidates in earlier development, alongside a substantial China-based pipeline tracked separately, extend the competitive set well beyond the three Western pivotal programmes profiled above. The full report profiles the broader landscape asset by asset.
Market inflection
2028

Wet AMD gene therapy does not need to beat anti-VEGF on efficacy, it only needs to match it while removing most of the injection burden. Phase 1/2 data already show 80 to 92% reductions in injection frequency and 73 to 80% of patients injection-free at 18 months. The first anticipated US approval in 2028 would mark the first realistic disruption to the Eylea HD and Vabysmo duopoly that has defined this market for over a decade. The VacZine Analytics and GeneScope Intelligence model quantifies the commercial consequences across the full range of adoption scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW wet AMD analysis spans disease burden, injection-burden displacement, the full Phase 3 competitor pipeline and patient-based revenue forecasting across ten high-income markets to 2040.

Patient-based forecast to 2040

Bottom-up modelling across 10 major high-income developed markets, tracking the transition from chronic anti-VEGF therapy to one-time gene therapy administration.

Competitor & pipeline review

Head-to-head assessment of 4D-150, ABBV-RGX-314 and ADVM-022: vector, route of administration, trial design and readout timing, alongside the broader pipeline.

Pricing & health economics

Low, base and high pricing scenarios benchmarked against Luxturna and Zolgensma precedents, with outcome-based and annuity contracting models assessed for payer acceptance.

Injection-burden displacement model

Quantifies the anti-VEGF injection burden today, and models the share of the treated population plausibly captured by one-time gene therapy under each scenario.

Disease burden & epidemiology

Updated global and regional prevalence, risk-factor analysis and the growing Asia-Pacific wet AMD burden, referenced against the current peer-reviewed literature.

Competitive & strategic implications

Disruption of the Eylea HD / Vabysmo duopoly, route-of-administration as a commercial differentiator, and a 12 to 24 month business development catalyst calendar.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the programme and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Programme / vectorDelivery routeGeographyTherapy profileRevenue scenario
4D-150 (AAV R100)IntravitrealUS + GlobalOffice-based, dual transgeneModelled
ABBV-RGX-314 (AAV8)SubretinalUS + EU5Surgical, pivotalModelled
ADVM-022 (AAV2.7m8)IntravitrealUS + GlobalOffice-basedModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseGlobalAllAll profiles$███m
Full model in the licensed workbook
10 markets · injection-burden model · 3 pricing scenarios
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the wet AMD gene therapy opportunity.

  • Executive presentation (~165 slides, PDF) - disease background, epidemiology, injection-burden analysis, the Phase 3 pipeline and pricing/health-economic rationale
  • Interactive MS-Excel forecast model - patient-based volume and revenue outputs to 2040, editable across epidemiology, diagnosis rate, anti-VEGF displacement curves and pricing
  • Pricing scenarios & health economic rationale - low, base and high price points, ICER framing, and Luxturna and Zolgensma precedents, plus outcome-based and annuity contracting models
  • Competitor intelligence - 4D-150, ABBV-RGX-314 and ADVM-022 head-to-head, plus the broader intravitreal, subretinal and China-based pipeline
  • Updated epidemiology module - global and regional AMD and wet AMD prevalence, risk factors and the Asia-Pacific burden trend
  • 10-market geographic build - major high-income developed markets, annual forecast to 2040, with North America, EU5 and rest-of-world views
Target audience

Built for organisations weighing the wet AMD opportunity

Most valuable to teams evaluating the wet AMD gene therapy market against their own pipeline, BD ambitions or investment thesis, particularly ahead of the 2027 to 2028 readout and approval window.

Gene therapy developers & BD

Positioning, competitive benchmarking and partnering economics for wet AMD candidates at any stage, vector or delivery route.

Corporate strategy (large pharma)

Validate market size and structure ahead of in-licensing, partnering or defensive positioning against the anti-VEGF franchise.

Investors & equity analysts

Independent assessment of market size and pipeline risk for due diligence on ophthalmology gene therapy assets.

Payers & market access

Budget-impact modelling for 2028-plus gene therapy launches, and the injection-burden-averted case for outcome-based contracting.

Researchers & academia

Comprehensive epidemiology, mechanism-of-disease and pipeline mapping for grant and translational planning.

Retinal specialists & clinicians

A structured view of the evolving treatment landscape to inform patient counselling and practice-planning decisions.

About this analysis · VAMVG003

VacZine Analytics has built independent, boutique intelligence on vaccine and infectious-disease markets since 2007. That same rigour, disease-first epidemiology paired with an independently constructed commercial model, now extends into gene therapy through our specialist division, GeneScope Intelligence. Wet AMD is one of the first titles in that programme: a high-volume indication where a chronic, injection-heavy standard of care meets a genuinely disruptive one-time therapy, and a commercial question, how fast, and how far, gene therapy can displace anti-VEGF, that generic market sizing cannot answer.

This February 2026 edition incorporates the Phase 2 durability data behind 4D-150, ABBV-RGX-314 and ADVM-022, and the pivotal trial designs now underway across all three programmes. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics and GeneScope Intelligence can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW & GeneScope Intelligence · VAMVG003 · Syndicated & bespoke

Syndicate the report - or commission the answer you need

Register your interest to help shape and secure the full syndicated MarketVIEW edition, which proceeds subject to sufficient client buy-in. Single-licence and multi-seat options follow on publication. Need something faster or more specific? VacZine Analytics and GeneScope Intelligence can be commissioned for bespoke, ad-hoc wet AMD analysis, a briefing call is included on request.